Zimmer Biomet Holdings, Inc.

For medtechs, the short term has become complicated almost beyond imagination, with markets and trade disrupted by geopolitical conflict, tariffs, and supply chain difficulties and even the Suez Canal

Biopharma merger and acquisition value for the first quarter of 2025 reached $38.4bn from 41 transactions, 22 of which had disclosed values. Making up almost 38% of that total was Johnson & Johnso

The Zimmer Biomet CPT hip system should be used only if no alternatives are available and patients have been warned of potential risks, the US Food and Drug Administration said in a 17 September saf

Johnson & Johnson MecTech says it has received US Food and Drug Administration 510(k) clearance for its first robotic-assisted platform for spine, targeting a commercial launch in the first half of 2